Formestane aromatase inhibitors

Description Results NMA

Clinical benefit (assessable) 1.17 [0.66; 2.06]

Objective response (assessable) 0.56 [0.15; 2.14]

Objective response (randomised) 0.56 [0.15; 2.14]

Clinical benefit (randomised) 1.17 [0.66; 2.06]

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

Clinical benefit (assessable) 1.10 [0.95; 1.28]

Objective response (assessable) 1.13 [0.85; 1.50]

Objective response (randomised) 1.12 [0.83; 1.51]

Clinical benefit (randomised) 1.10 [0.93; 1.30]

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

Clinical benefit (assessable) 0.89 [0.69; 1.15]

Objective response (assessable) 1.01 [0.52; 1.97]

progression-free survival (reported or calculated) 0.93 [0.42; 2.05]

Objective response (randomised) 0.99 [0.51; 1.92]

Clinical benefit (randomised) 0.87 [0.67; 1.12]

thromboembolic 0.13 [0.02; 1.02]

hot flushes 1.30 [0.88; 1.92]

vaginal bleeding 0.08 [0.01; 0.57]

Objective response (assessable) 1.25 [0.88; 1.77]

nausea 0.98 [0.40; 2.44]

progression-free survival (reported or calculated) 1.06 [0.61; 1.85]

Objective response (randomised) 1.24 [0.87; 1.78]

rash 1.31 [0.30; 5.79]

hot flushes 1.20 [0.51; 2.85]

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration: